Leslie M. Shaw, Ph.D.
Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania
Director, Alzheimer's Disease Neuroimaging, Initiative Biomarker Core Laboratory, University of Pennsylvania
Department: Pathology and Laboratory Medicine
Contact information
Hospital of the University of Pennsylvania
7.103 Founders Pavilion 3400 Spruce Street
Philadelphia, PA 19104
7.103 Founders Pavilion 3400 Spruce Street
Philadelphia, PA 19104
Office: (215) 662-6575
Fax: (215) 662-7529
Fax: (215) 662-7529
Education:
B.S. (Cum Laude, Chemistry)
LeMoyne College, Syracuse, New York, 1962.
Ph.D. (Biochemistry)
S.U.N.Y. at Upstate Medical Center, 1968.
Permanent linkB.S. (Cum Laude, Chemistry)
LeMoyne College, Syracuse, New York, 1962.
Ph.D. (Biochemistry)
S.U.N.Y. at Upstate Medical Center, 1968.
Description of Research Expertise
Development, validation and implementation of neurodegenerative diseases biomarkers in cerebrospinal fluid and plasma into treatment trials and clinical studies (eg, ADNI study; UPENN ADRC; PPMI study). These studies include the use of manual and highly automated immunoassays and for amyloid beta(1-42), U-p53AZ and for total tau the use of high sensitivity UPLC/tandem mass spectrometry. Multi-modal statistical analyses of these study data to address several questions including the diagnostic utilities of these biomarkers; assessments of the longitudinal trajectories of these biomarkers in AD, MCI and cognitively normal controls to assess the neuropathological changes over time in these individuals.Description of Clinical Expertise
Measurement and interpretation of the toxicokinetics of drugs and toxins in patients affected by them. Interpretation of the pharmacokinetics of immunosuppressant maintenance medications in transplant patients.Description of Other Expertise
Development and implementation of mass spectrometry-based methods for measuring small molecules of clinical utility including therapeutic drugs, toxins and special chemistry tests including Xylazine; 25-OH vitamin D; and biologicals, eg, Infliximab. Development, validation and implementation of plasma based Alzheimers Disease biomarkers.Selected Publications
Brown CA, Mundada NS, Cousins KAQ, Sadeghpour N, Lyu X, McGrew E, Korecka M, Chen-Plotkin A, Xie L, Wisse LEM, Detre JA, McMillan CT, Lee EB, Nasrallah IM, Das SR, Mechanic-Hamilton D, Yushkevich PA, Shaw LM, Wolk DA; Alzheimer’s Disease Neuroimaging Initiative. : Evaluation of Copathology and Clinical Trajectories in Individuals with Tau-Clinical Mismatch JAMA Neurol. February 2026.Lang YR, Vrillon A, Pasternak S, Blazhenets G, Soleimani-Meigooni D, Ravinovici GD, Weiner MW, Hantke N, Silbert L, Schwartz DL, Ezer AL, Segev OL, Ganmore I, Ravona-Springer R, Yaffe K, Landau SM, Korecka M, Shaw LM, Joie R, Gardner RC. Effect of prior traumatic brain injury on Alzheimer's disease blood biomarkers in Vietnam Veterans. : Effect of prior traumatic brain injury on Alzheimer's disease blood biomarkers in Vietnam Veterans. medRxiv [Preprint] January 2026.
Xiong C, Luo J, Wolk DA, Shaw LM, Roberson ED, Bateman RJ, Morris JC, Schindler SE. : Age of plasma Aβ42/40 positivity in Black and White individuals Alzheimers Dement. January 2026.
Korecka M, Uzunova V, Delatour V, Zetterberg H, Shaw LM. : Reference Material for Amyloid Beta 1‐40 in Human CSF: Joint Initiative of the University of Pennsylvania, JRC and IFCC Alzheimers Dement January 2026.
Petersen KK, Milà‐Alomà M, Tosun D, Li Y, Saef BA, Shaw LM, Dage JL, Zetterberg H, Du‐Cuny L, Xiong C, Barthélemy NR, Bateman RJ, Holtzman DM, Morris JC, Bannon AW, Potter WZ, Schindler SE. : Predicting onset of Alzheimer disease symptoms with a plasma %p‐tau217 clock Alzheimers Dement. December 2025.
Wang TC, Timsina J, Jiang C, McCartney DL, Tao F, Anastasi F, Genius P, Rodríguez‐Fernández B, Navarro A, Puerta R, van der Lee SJ, Marioni RE, Bertram L, Michael NW, Sims R, Vilor‐Tejedor N, Bradley J, Ali M, Wang C, Liu M, Ruiz A, Fernandez MV, Williams J, Budde JP, Tijms B, Castillo A, Blennow K, Zetterberg H, Lleo A, Lee VMMY, Heslegrave AJ, Pastor P, Peskind ER, Saykin AJ, Morris JC, Schindler SE, Holtzman DM, Riemenschneider M, Albert MSS, Van Deerlin VM, Shaw LM, Sung YJJ, Hohman TJ, Cruchaga C, Dumitrescu L. : Sex‐stratified GWAS meta‐analyses reveal novel sex‐specific association with CSF biomarkers of Alzheimer's Disease Alzheimers Dement. December 2025.
Vrillon A, Blazhenets G, Lang YR, Lagarde J, Chiotis K, Raya MA, Soleimani‐Meigooni DN, Rabinovici GD, Weiner MW, Silbert LC, Hantke N, Schwartz D, Livny A, Lesman‐Segev OH, Yaffe K, Shaw LM, Landau SM, Gardner RC, Joie RL. : Evaluating agreement between visual read and quantification of amyloid PET in the ADNI‐DOD cohort Alzheimers Dement. December 2025.
Nowling B, Radhakrishnan H, Olm CA, Cook PA, Cousins KAQ, Shaw LM, Snyder A, Irwin DJ, McMillan CT, Massimo L, Nasrallah IM, Phillips JS. : Non‐amnestic AD syndrome would exhibit WM differences from amnestic and other non‐amnestic syndromes Alzheimers Dement. December 2025.
Brown CA, Das SR, Cousins KAQ, Xie L, McGrew E, Korecka M, Tropea TF, Chen‐Plotkin A, Detre JA, McMillan CT, Lee EB, Nasrallah IM, Yushkevich PA, Mechanic‐Hamilton D, Shaw LM, Wolk DA. : Tau Cognitive Mismatch in Alzheimer's Disease Predicts Presence of Co‐Pathology and Diverging Disease Trajectory Alzheimers Dement. December 2025.
Jiang X, Hoang TD, Shaw LM, Jacobs DR Jr, Nasrallah IM, Bryan RN, Yaffe K. : Alzheimer disease blood biomarkers and cognition in midlife Alzheimers Dement. December 2025.